These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33846219)

  • 1. Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein.
    Hyun JW; Kim Y; Kim SY; Lee MY; Kim SH; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33846219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG
    Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis.
    Liu C; Zhou W; Sun X; Zhang X; Xiao H; Yang H; Lin H; Lu Y; Liu Z; Qiu W; Kermode AG; Yang X; Wang Y
    Mult Scler Relat Disord; 2024 May; 85():105478. PubMed ID: 38457885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder.
    Kim H; Kim HJ; So J; Kim JY; Jung HJ; Kim S; Seo D; Kim HJ; Song HE; Lim YM; Yoo HJ; Lee EJ
    Mult Scler Relat Disord; 2024 May; 85():105551. PubMed ID: 38564996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Aktas O; Smith MA; Rees WA; Bennett JL; She D; Katz E; Cree BAC;
    Ann Neurol; 2021 May; 89(5):895-910. PubMed ID: 33724534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
    Li Y; Liu Y; Zhao W; An X; Zhang F; Zhang TX; Liu Y; Du C; Zeng P; Yuan M; Zhang N; Zhang C
    J Neuroimmunol; 2023 Nov; 384():578218. PubMed ID: 37801952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
    Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis.
    Meier S; Willemse EAJ; Schaedelin S; Oechtering J; Lorscheider J; Melie-Garcia L; Cagol A; Barakovic M; Galbusera R; Subramaniam S; Barro C; Abdelhak A; Thebault S; Achtnichts L; Lalive P; Müller S; Pot C; Salmen A; Disanto G; Zecca C; D'Souza M; Orleth A; Khalil M; Buchmann A; Du Pasquier R; Yaldizli Ö; Derfuss T; Berger K; Hermesdorf M; Wiendl H; Piehl F; Battaglini M; Fischer U; Kappos L; Gobbi C; Granziera C; Bridel C; Leppert D; Maleska Maceski A; Benkert P; Kuhle J
    JAMA Neurol; 2023 Mar; 80(3):287-297. PubMed ID: 36745446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases.
    Plantone D; Stufano A; Righi D; Locci S; Iavicoli I; Lovreglio P; De Stefano N
    Sci Rep; 2024 Mar; 14(1):6429. PubMed ID: 38499607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity.
    Bose G; Healy BC; Saxena S; Saleh F; Glanz BI; Bakshi R; Weiner HL; Chitnis T
    Neurol Neuroimmunol Neuroinflamm; 2023 Nov; 10(6):. PubMed ID: 37813595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa.
    Wang J; Wang J; Xie W; Liu J; Feng J; Wei W; Li M; Wu L; Wang C; Li R
    Int Immunopharmacol; 2023 Mar; 116():109761. PubMed ID: 36709595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis.
    Sainz-Amo R; Rodero Romero A; Monreal E; Chico García JL; Fernández Velasco JI; Villarrubia N; Veiga González JL; Sainz de la Maza S; Rodríguez Jorge F; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2024; 15():1454474. PubMed ID: 39224593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain.
    Hyun JW; Kim SY; Kim Y; Park NY; Kim KH; Kim SH; Kim HJ
    Mult Scler; 2022 May; 28(6):993-999. PubMed ID: 34965770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.
    Vardakas I; Dorst J; Huss A; Mayer B; Fangerau T; Taranu D; Tumani H; Senel M
    Eur J Neurol; 2024 Aug; 31(8):e16323. PubMed ID: 38700322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes.
    Bose G; Healy BC; Saxena S; Saleh F; Paul A; Barro C; Lokhande HA; Polgar-Turcsanyi M; Anderson M; Glanz BI; Guttmann CRG; Bakshi R; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2023 Jun; 74():104695. PubMed ID: 37060852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Glial Fibrillary Acidic Protein as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.
    Shaygannejad A; Rafiei N; Vaheb S; Yazdan Panah M; Shaygannejad V; Mirmosayyeb O
    Medicina (Kaunas); 2024 Jun; 60(7):. PubMed ID: 39064479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.